Cadrenal Therapeutics has provided a Q2 2023 corporate update, highlighting an expanded focus for tecarfarin development for patients with implanted medical devices such as LVADs for heart diseases, a market opportunity of approximately $600 million per year in the U.S. The company completed a $7.5 million private placement priced at-the-market under Nasdaq rules. As of August 14, 2023, cash balances were $9.6 million.